Workflow
I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer
天境天境(US:IMAB) Yahoo Finance·2025-09-24 07:12

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. I-Mab stands second among them. I-Mab (NASDAQ:IMAB) is a U.S.-based biotechnology company focused on precision immuno-oncology, developing differentiated therapies for cancer. Its lead candidate, givastomig, is a bispecific antibody targeting Claudin 18.2 and 4-1BB, designed to selectively activate T cells within the tumor microenvironment, aiming to maximize anti-tumor effects while reducing common toxic ...